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action of the drug-carrier complex and the skin surface, 
which becomes possible by the lipid nature and nanosize of 
the carrier and appears not to be derived by testing drug re-
lease. Interestingly, PC and PD uptake from SLN even result-
ed in epidermal targeting. Thus, SLNs are not only able to 
improve skin penetration of topically applied drugs, but may 
also be of particular interest when specifically aiming to in-
fluence epidermal dysfunction. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Human skin is tremendously efficient in protecting 
the organism against the uptake of xenobiotics including 
topically applied drugs. The stratum corneum, formed by 
corneocytes imbedded in a lipid matrix mainly com-
posed of ceramides, cholesterol and free fatty acids (C 24 –
C 26 ), represents the primary barrier  [1] . Surmounting this 
skin barrier is essential in the topical treatment of skin 
diseases. For about 20 years, solid lipid nanoparticles 
(SLNs) have been studied intensely as drug carrier system 
for parenteral  [2, 3] , peroral  [4, 5] and dermal application 
 [6, 7] . The colloidal character (particle size between 100 
and 500 nm), the solid state of the particles and physio-
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 Abstract 
 Solid lipid nanoparticles (SLNs) can enhance drug penetra-
tion into the skin, yet the mechanism of the improved trans-
port is not known in full. To unravel the influence of the drug-
particle interaction on penetration enhancement, 3 gluco-
corticoids (GCs), prednisolone (PD), the diester prednicarbate 
(PC) and the monoester betamethasone 17-valerate (BMV), 
varying in structure and lipophilicity, were loaded onto SLNs. 
Theoretical permeability coefficients (cm/s) of the agents 
rank BMV (–6.38)  6 PC (–6.57)  1 PD (–7.30). GC-particle inter-
action, drug release and skin penetration were investigated 
including a conventional oil-in-water cream for reference. 
Both with SLN and cream, PD release was clearly superior to 
PC release which exceeded BMV release. With the cream, the 
rank order did not change when studying skin penetration, 
and skin penetration is thus predominantly influenced by 
drug release. Yet, the penetration profile for the GCs loaded 
onto SLNs completely changed, and differences between 
the steroids were almost lost. Thus, SLNs influence skin pen-
etration by an intrinsic mechanism linked to a specific inter-
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logical lipids forming the particle matrix, as well as well-
tolerated surfactants used for particle stabilization, make 
SLNs an interesting alternative to other nanosized sys-
tems, such as liposomes, nanostructured lipid carriers, 
microemulsions and polymeric particles for improving 
skin therapy  [8, 9] . Yet, until today there is only limited 
data on the mechanism of drug transport into the skin  [7, 
10] . Making contact with the skin surface, the carrier ma-
trix appears to dissolve, and this favors the interaction of 
carrier lipids and skin lipids and the penetration of the 
loaded guest molecules  [11–13] . Interestingly, uptake 
from SLNs is clearly superior to uptake from particles 
built up from both solid lipids and oils (nanostructured 
lipid carriers)  [14, 15] . Active pharmaceutical ingredients 
or marker agents (dyes or spin probes) can be incorpo-
rated into the lipid matrix of SLNs  [14] or attached to the 
particle surface  [15–18] . In fact, even subcompartments 
of spin probe localization have been observed  [16] . Up-
take enhancement is 4- to 8-fold over cream with dyes 
incorporated or attached, whereas epidermal targeting 
was seen only with guest molecules attached to the sur-
face  [15, 18, 19] .
 To unravel the mechanism of SLN enhanced uptake in 
more detail, we studied the skin penetration of glucocor-
ticoids (GCs): prednisolone 17-ethylcarbonate 21-propio-
nate (prednicarbate, PC) and betamethasone 17-valerate 
(BMV) – which are frequently used in the treatment of 
inflammatory skin diseases  [9, 20] – as well as predniso-
lone (PD). The 3 GCs are close in molecular weight and 
molecular volume but vary in lipophilicity (octanol-wa-
ter partition coefficient) and structure ( table 1 ). Aiming 
for a deeper insight into carrier-related effects on drug 
concentrations at the active site, drug release and skin 
penetration were compared from SLN dispersion and an 
oil-in-water cream (DAC Cremor basalis). Investigations 
of drug release and skin penetration in parallel are crucial 
to estimate the potential of a drug carrier system and – 
most importantly – to unravel the carrier effect on skin 
penetration.
 Material and Methods 
 Material 
 The GCs betamethasone (BM), PD and BMV were supplied by 
Sigma-Aldrich (Munich, Germany); PC was a gift from Sanofi-
Aventis (Frankfurt a.M., Germany). Compritol  888 ATO (glyc-
eryl behenate) was a gift from Gattefossé (Weil a.Rh., Germany), 
the surfactant Poloxamer  188 was supplied by BASF (Ludwigs-
hafen, Germany) and base cream (Cremor basalis, oil-in-water 
cream, as described by the Deutscher Arzneimittelcodex 2004, 
containing glycerin monostearate 4%, cetylalcohol 6%, macrogol 
20-glycerol monostearate 7%, medium-chain triglycerides 7.5%, 
propylene glycol 10%, white vaseline 25.5% and water 40%) was 
obtained from Caelo (Hilden, Germany). All other reagents were 
supplied by VWR (Darmstadt, Germany) and were of the highest 
quality available.
 Methods 
 Preparation of GC-Loaded SLN Dispersion and Cream 
 SLNs, composed of 10% Compritol  888 ATO, 2.5% Polox-
amer  188 and 0.1% (0.075–0.3% for the parelectrical spectros-
copy) of a GC, were prepared by high-pressure homogenization 
as described previously  [14, 21] . Briefly, the lipid was melted at ap-
proximately 95   °   C to dissolve or disperse the GC. Following the 
addition of the aqueous surfactant solution of about 85  °  C, a pre-
mix was formed using a rotor-stator mixer and was then passed 
through the homogenizer (EmulsiFlex C5; Avestin, Mannheim, 
Germany) at 90   °   C and 500 bar. The homogenizer ran continu-
ously for 2.5 min equivalent to 3 cycles for 20 g of the dispersion. 
The obtained nanoemulsion was gently cooled down to room 
temperature without stirring to form SLNs. All dispersions were 
stored in silanized vials at 8  °  C for up to 3 months.
 To produce a GC-loaded cream, small amounts of the base 
cream were added to the GC and homogenized at ambient tem-
perature using a pestle and mortar until the final GC concentra-
tion of 0.1% was obtained.
 Characterization of the SLNs 
 Mean particle size (z-average) and the polydispersity index 
(PI, a measure of the distribution width) were determined by pho-
ton correlation spectroscopy (Malvern Zetasizer Nano-ZS, Mal-
vern Instruments, Malvern, UK). In addition, laser diffractome-
try (LD, Coulter LS 230; Miami, Fla., USA) served to detect larger 
particles; the maximum size of 95% of the volume of the particles 
(LD95) is reported. The diffraction patterns were analyzed using 
the Mie model (fluid refractive index of 1.335, real sample refrac-
tive index of 1.456 and imaginary sample refractive index of 0.01). 
Recrystallization of the GCs during the storage of the particles 
was inspected by polarized light microscopy (Leitz-Orthoplan; 
Leica, Wetzlar, Germany). The methods are described in detail 
elsewhere  [10, 22] . Furthermore, the lipid dispersions were ana-
lyzed by differential scanning calorimetry (DSC, Mettler DSC 
Table 1. P hysicochemical data of PD, PC and BMV and QSPR
PD PC BMV
MW, g/mol 360.45 488.57 476.58
MV, cm3/mol 274.7 388.5 382.3
PSA, Å2 94.8 116.2 100.9
logP 1.69 3.82 3.98
logKp –7.30 –6.57 –6.38
MW = Molecular weight; MV = molecular volume; PSA = po-
lar surface area; logP = octanol-water partition coefficient; Kp = 
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821 e ; Mettler Toledo, Giessen, Germany). Samples of about 20 mg 
were accurately weighted in 40-  l aluminum pans. DSC scans 
were recorded from 15 to 85   °   C with a heating rate of 5   °   C/min. 
The recrystallization of the lipid nanoparticles was examined, 
and the crystallization index CI was calculated from the enthalpy 










CI J g concentration %
enthalpy J g
           (1)
 Interaction of the GCs and SLNs was studied by parelectric 
spectroscopy. The theoretical background and the method are de-
scribed in detail elsewhere  [16, 24] . Briefly, the dependence of par-
ticle mobility and density of the dipoles on the increasing drug 
concentration (0–0.3% of the GC) was measured by a frequency 
analyzer (type ZVR, Rohde and Schwarz, München, Germany). 
Results allow to distinguish between attachment of a guest mol-
ecule to the surface (parabolic relationship) or the incorporation 
of the agent into the matrix of a carrier system (linear relation-
ship).
 Drug Release Studies 
 GC release from SLNs and cream was studied using Franz dif-
fusion cells  [25, 26] , 15 mm in diameter (surface area 1.76 cm 2 ) and 
of 12 cm 3 volume of the receiver chamber (PermeGear, Bethlehem, 
Pa., USA). A presoaked polyamide membrane (pore size 0.2   m, 
diameter 25 mm, Sartorius AG, Goettingen, Germany) separated 
the donor and the receptor compartments. The receptor fluid 
(phosphate-buffered saline, PBS, pH 7.4) was continuously stirred 
at 500 rpm; the temperature was maintained at 33.5  °  C by a circu-
lating water bath. An infinite dose (500   l) of the formulation was 
applied after 30 min equilibration, removal of a 500-  l predose 
sample of the receptor fluid and replacement by fresh PBS. The 
donor compartment was sealed with Parafilm  to prevent evapo-
ration of the formulation. Further aliquots of 500   l receptor flu-
id were withdrawn repeatedly (0.33, 0.66, 1, 2, 3, 4, 5, 6, 7 and 8 h; 
with replacement) and stored at –20  °  C. The samples were analyzed 
by high-performance liquid chromatography (HPLC) after ex-
traction. The cumulative GC amount released, expressed in mi-
crograms per square centimeter, is plotted against the square root 
of time (h 0.5 )  [27] , also called Higuchi plot. The flux, the mass of 
test substance passing through a unit area of the membrane (1.76 
cm 2 ) per unit of time under steady-state conditions (in   g/cm 2 /
h 0.5 ) as well as the relative lag time (abscissa intercept point, h 0.5 ) 
were calculated from the slope of the graph  [28] using an auto-
mated approach  [29] adjusting the h 0.5 time. All experiments were 
repeated 9 times, and the average values were taken.
 Skin Penetration Studies 
 Using human skin, cutaneous absorption can be studied ex 
vivo by a validated test protocol  [30, 31] . Human full-thickness 
abdominal or breast skin was from females aged 18–69 years (with 
permission) subjected to plastic surgery. Placed in ice-cold cloth, 
skin was transferred to the laboratory immediately, taking care to 
avoid contamination of the skin surface by subcutaneous lipids 
and stored frozen at –20   °   C for at least 24 h, not exceeding 6 
months. On the day of experiment, thawed skin was mounted into 
the Franz diffusion cells, the stratum corneum facing the air and 
the lower surface in contact with the magnetically stirred receptor 
fluid. The experimental setup was identical with that of the re-
lease study. After equilibration for 30 min, 500   l (infinite dose) 
of the formulation was applied to the skin surface for 6 h. Then 
surplus material was carefully removed by a cotton swab soaked 
in PBS, and the skin was stripped twice with adhesive tape; the 
tape strips with remaining nonabsorbed GC were discarded. Skin 
samples were stored at –20  °  C. In order to quantify the GC amount 
in the different skin layers, the skin samples were cut at –24  °  C into 
horizontal slices of 50   m using a freeze-microtome (Frigocut 
2800 N; Leica Microsystems, Bensheim, Germany). Two consecu-
tive slices were pooled and 500   l of a saturated sodium fluoride 
solution (120 mg/ml) were added to inhibit esterases of the skin 
 [32] . The samples were analyzed by HPLC to quantify native GCs 
and metabolites in the different skin layers (0–400   m; steps of 
100   m) after 6-hour exposure. Results are expressed as the 
amount of total drug, each representing the native drug (PD, PC 
and BMV) plus its degradation products or metabolites, respec-
tively.
 Uptake by human skin was studied in triplicate (skin of 3 do-
nors) and at least 3 repetitions for cream and SLN (n = 3), respec-
tively. GC-loaded SLN dispersions were tested in parallel using 
the skin of the same donors. This holds also true when testing GC 
creams.
 Quantification of the GCs  
 PC, BMV and their degradation products as well as PD were 
quantified by HPLC (LaChrom TM HPLC system; Merck-Hita-
chi, Darmstadt, Germany)  [19, 32] . BM served as internal stan-
dard for PD and PC determination, whereas PD was the internal 
standard of BMV quantification. Since GC 21-esters can be 
cleaved by skin esterases  [32] and GC 17-monoesters are degrad-
ed nonenzymatically  [33] and may also rearrange spontaneous-
ly to the respective more stable 21-esters  [34–36] , formulations, 
receptor fluid and skin were analyzed for degradation products. 
Prednisolone 17-ethylcarbonate (P17EC), prednisolone 21-eth-
ylcarbonate (P21EC) and betamethasone 21-valerate (BM21V) 
were identified according to their retention times determined 
previously and quantified by relating UV absorbance (peak 
area) to PC or BMV, respectively. The retention times are PD 6.9 
min, BM 8.3 min, P17EC 9.8 min, P21EC 11.1 min, BMV 13.0 
min, PC 13.6 min and BM21V 14.0 min. Limits of quantification 
are 61 ng/ml (PC), 90 ng/ml (PD), 98 ng/ml (BM) and 119 ng/ml 
(BMV). The linear correlation of peak area and concentration is 
given up to 50   g/ml (correlation coefficient  1 0.994).
 To verify the GC concentration in creams and SLN dispersions 
and to check for potential hydrolysis of GC esters (PC, BMV), all 
preparations were extracted and subjected to HPLC analysis. 100 
mg of cream was dispersed in 10 ml of chloroform following ad-
dition of internal standard (100   l of 10 –4  M GC in methanol). The 
samples were vortexed, and 1 ml of the solution was withdrawn 
and exsiccated by vacuum rotation. Residues were extracted 3 
times by 500   l of methanol. The combined extracts were once 
more exsiccated in a vacuum. The SLN dispersions were diluted 
1: 100, and the internal standard was added (20   l of 10 –4  M GC in 
methanol). Samples were extracted 3 times by 500   l of ethyl ac-
etate, and the combined extracts were exsiccated by vacuum rota-
tion. Residues were dissolved in 500   l methanol and the exsicca-
tion was repeated. Finally the extracts from the creams and SLN 
dispersions were dissolved in 200   l methanol, centrifuged and 
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 For the analysis of drug release and skin penetration, GCs and 
their metabolites were quantified in PBS (receptor fluid) and ex-
cised human skin (skin penetration only). While receptor fluid 
was extracted immediately after defrosting, the skin slices in satu-
rated sodium fluoride solution were first subjected to 5 freeze-
thaw cycles to disrupt membranes before extraction. Following the 
addition of the internal standard, the samples were extracted 3 
times by 500   l of ethyl acetate. The combined extracts were exsic-
cated by vacuum rotation, dissolved in 500   l of methanol and 
exsiccated again. The residues were dissolved in 100   l of metha-
nol and 50   l were injected into the HPLC. Recovery of the steroids 
was 75% from human skin  [32] and exceeded 82% from PBS  [34] .
 Calculation of Physiochemical Data, Quantitative
Structure-Permeability Relationship (QSPR) 
 Besides molecular weight and lipophilicity, molecular polar 
surface area is reported to influence drug transport  [37, 38] . To 
include this parameter, polar surface area calculation was per-
formed as described  [38] . Furthermore, the molecular volumes of 
the 3 steroids were calculated using the ACD/Labs Software (Ad-
vanced Chemistry Development Inc., Ontario, Calif., USA) and 
the permeability coefficient K p as described by Potts and Guy  [39] :
 logK p (cm/s) = 0.71 logP – 0.0061   MW – 6.3              (2)
 where logP = octanol-water partition coefficient and MW = mo-
lecular weight.
 Data Analysis 
 Data are given as arithmetic mean values  8 standard devia-
tion. Additionally, the results of GC skin penetration are summa-
rized in a box plot with the median, the minimum, the maximum 
and the 0.25 and 0.75 quartiles. In order to verify the differences 
of the drug release (n = 9), data were subjected to the nonparamet-
ric Kruskal-Wallis test, followed by the Dunn/Bonferroni proce-
dure, in case of significance (GraphPad Prism  version 5.03). 
Thus p  ^  0.05 is regarded to indicate a difference. 
 Results and Discussion 
 Physicochemical properties of the active agents ( ta-
ble 1 ) as well as the characteristics of the formulation (ex-
cipients and dosage form) influence skin penetration. In-
vestigations on drug release and skin penetration are in-
dispensable to optimize the formulations for a topical 
therapy as insufficient drug release can result in low up-
take by the skin. Moreover, these experiments are also 
needed for a deeper insight into the interaction of skin, 
carrier system and the active ingredient, and for under-
standing the function of the carrier systems when aiming 
at advanced technological approaches.
 Characterization of the Formulations 
 Particle size, drug loading, drug stability and the phys-
ical state of the lipid are the major properties under inves-
tigation for a characterization of the physical and chemi-
cal (long-term) stability of the SLNs  [10, 40] . SLN disper-
sions, both loaded with the 3 GCs and nonloaded, were 
characterized on day 1 and day 39 after production by de-
termination of particle size by LD and photon correlation 
spectroscopy, phase transition of the lipid matrix with 
DSC and GC expulsion by polarized light microscopy. 
Moreover, HPLC was used to quantify the concentrations 
of the active agents and to inspect for degradation prod-
ucts caused by the thermal load during production.
 The main purpose of this study, however, was to exam-
ine the GC-particle interaction and its influence on skin 
penetration. Therefore, SLNs uniform in size and crystal-
linity were produced according to a standardized proto-
col. While PC and BMV were soluble in the lipid, PD was 
dispersed in the lipid matrix after heating for 1 h to about 
95  °  C. Destroying any crystal lattice of the bulk material 
by a sufficiently long heating period above the melting 
point is recommended in order to avoid the lipid memory 
effect and to enable a new crystallization. Furthermore, 
the solubility is a time-depending step but has to be in ac-
cordance with the thermostability of the agent. The mean 
particle size of the 3 SLN dispersions was 173  8 4 nm with 
a PI of 0.14  8 0.02 on day 1; size and size distribution did 
not change within 39 days (photon correlation spectros-
copy: 175  8 5 nm and PI 0.17  8 0.01). LD measurements 
confirm this result (LD95: 272  8 9 nm day 1 and 280  8 
10 nm day 39), microparticles were not detectable by LD 
and light microscopy. The GC-free SLNs were close in 
particle size (mean 169 nm, PI 0.13, LD95 267 nm).
 The mode of GC-lipid interaction during the produc-
tion process turned out to be relevant for stability. Where-
as PC and BMV could be dissolved in the melted lipid, PD 
was dispersed. By light microscopy PD crystals were de-
tected in the 0.1% PD SLN dispersion after 1 week, where-
as the 0.1% PC and the 0.1% BMV SLN dispersions were 
stable for at least 4 weeks. Hence, drug release and skin 
penetration studies were carried out within 3 days after 
production. Additional investigations showed a time de-
pendence of the drug expulsion in relation to the lipid-
GC ratio. Drug crystals were detected after 24 h with a 
0.3% PC-loaded SLN dispersion (same composition), yet 
a 0.075% PC-loaded SLN dispersion was stable for more 
than 3 months. Crystallization is due to a progressive 
cure of lattice imperfections during storage. Most of the 
triglyceride matrix is present in the highly organized   -
modification limiting the drug loading capacity of SLNs 
composed of triglycerides  [23] . DSC results revealed high 
crystallinity of the SLNs made of Compritol (crystalliza-
tion index 94  8 3%) not increasing upon storage, which 
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 On the first day after production the GC concentra-
tions in the SLN dispersions were quantified by HPLC. 
BMV SLNs (loading 106.8  8 1.4% of target value) showed 
limited thermal stability after homogenization as BMV 
made up 87.2  8 0.2% of the total GC, and the degrada-
tion products BM21V (12.5  8 0.2%) and BM (0.3  8 
0.0%) could be detected in relevant amounts. In contrast, 
with PC (103.1  8 3.2% of target value) degradation prod-
ucts were below the limit of quantification. Surprisingly, 
just 82.5  8 3.5% of PD was found in the final SLN disper-
sion; an additional peak appearing in the HPLC chro-
matogram at 8.3 min suggests that PD undergoes degra-
dation during the production. Quantifying this peak by 
relating UV absorbance (peak area) to PD led to the as-
sumption that the additional peak (18.4  8 7.7%) repre-
sents a degradation product, matching the missing drug 
amount. In fact, the sum of PD and the degradation prod-
uct was 100.9  8 6.2% of the target value. PD is suscep-
tible to degradation which involves the 20-keto group re-
sulting in the formation of the respective 17-ketosteroid 
 [42] ; instability is enhanced by higher temperatures  [43] . 
Verification of this product, however, was excluded as a 
reference substance was not available. The degradation 
product was considered in the calculation of drug release 
and skin penetration, whenever it appeared.
GC concentrations in the creams were quantified, too. 
PC (total 103.9  8 2.7%; 98.3  8 1.3% PC and 1.7  8 1.3% 
P17EC) and BMV (total 100.7  8 5.8%; 93.5  8 1.9% BMV, 
5.9  8 1.7% BM21V and 0.6  8 0.2% BM) showed only mi-
nor degradation. This is well explained by the lack of a 
heating step. Once more, the concentration of PD (95.8  8 
2.7%) in the cream was slightly below the target concen-
tration, but no additional peak was detected. Since GC 
release and skin penetration experiments used the infinite 
dose approach, the small discrepancy is negligible.
 Results of the parelectric spectroscopy revealed a lin-
ear relation of dipole mobility and the GC concentration 
(data are not shown). Thus, the 3 steroids were incorpo-
rated in the lipid matrix of the SLNs. Earlier studies  [19] 
indicated that SLN composition and production param-
eters strongly influence the drug-particle interaction.
 GC Release: Cream 
 Drug release studies were performed using a Franz 
diffusion cell with a polyamide membrane as diffusion 
barrier. The cumulative amount of GC released (  g/cm 2 ) 
is plotted against the square root of time (h 0.5 ). For topical 
formulations a linear relationship between the drug re-
leased and the square root of time was shown, if less than 
30% of the applied drug is released  [44] . This holds true 
both with active agents fully dissolved  [45] or suspended 
in the formulation  [46] .
 Figure 1 a shows steroids released from the cream ver-
sus the square root of time; all 3 steroids were slowly re-
leased. Yet, PD was released clearly faster than PC and 
BMV. After 8 h almost 9% of PD was released (44.3  8 4.5 
  g) but less than 1% of the other steroids (4.3  8 0.4 and 
1.8  8 0.2   g for PC and BMV, respectively; p  ^  0.05). 
 Table  2 summarizes the calculated kinetic constants, 
fluxes and relative lag times of the systems. The flux of 
PD exceeding PC and BMV flux 8.5- and 15-fold (p  ^  
0.05), underlines a clear superiority of the PD cream 
when aiming for fast release. Moreover, the short rela-
tive lag times, ranging from 0.2  8 0.0 h 0.5 (PD) to 1.2  8 
0.2 h 0.5 (BMV), prove that the polyamide membrane is 
highly permeable for the steroids and that membrane re-
tention is not the rate-limiting step. The inner structure 
of the cream and the physicochemical properties of the 
GCs ( table 1 ) can explain the release pattern. Dissolution 
of the steroids by the cream (oil-in-water emulsion) was 
given as no GC crystals were detectable by light micros-
copy. Due to the 2-phase system of the cream, the agents 
will be partitioned between the inner oil and the outer 
aqueous phase. Surely, the less lipophilic PD is dissolved 
to a higher level in the outer water phase and can pass the 
membrane much faster than highly lipophilic PC and 
BMV which will be favorably dissolved in the inner lipid 
phase of the cream and therefore have a longer diffusion 
pathway. Thus, GC release from the cream is a function 
of the physicochemical properties of the active agent, 
meaning its partition between the water and the oil phase 
of the cream.
 Investigating GC release from cream, no PC and PD 
degradation products were found in the receptor fluid. 
However, BMV proved less stable. BMV (77.6  8 3.2%) 
was the main steroid in the receptor fluid after 8 h, fol-
lowed by the more stable isomer  [34] BM21V (22.0  8 
3.2%) and the hydrolysis product BM (0.4  8 1.2%). This 
result is in accordance with the limited stability of BMV 
(43.4  8 3.8% BM21V, 8 h, 33.5  °  C) in PBS and a previous 
report on BMV diffusion of a living skin equivalent  [33] 
and higher stability of PC (3.3  8 0.3% PC17EC; 3.8  8 
0.3% P21EC, 8 h, 33.5  °  C).
 GC Release: SLNs 
 Release profiles of SLNs can be controlled by the lipid 
matrix, surfactant concentration and production condi-
tions (e.g. temperature)  [21, 47] . As with the cream, GC 
release ranged in the order PD  1 1 PC  1 BMV ( fig. 1 b;
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2-phase kinetics ( fig. 2 ): at 3 h about 25% of PD was re-
leased but just another 7% in the following 5 h. As PD 
solubility is 142   g/ml in water  [48] and 223   g/ml in dif-
ferent buffers  [49] , a sink condition during the experi-
ment (13.5   g/ml) was provided. Studying Compritol-
based SLNs, zur Mühlen and Mehnert  [21] observed a 
similar biphasic release profile for PD, too, changing with 
the production conditions and the lipid matrix. The rath-
er high aqueous solubility of PD and the high tempera-
ture during the production should allow PD to partition 
between the two phases  [47, 50] . In contrast, the highly 
lipophilic PC and BMV appear to remain within the lip-
id matrix since prolonged release and obviously 1-phase 
kinetics are observed ( fig. 2 ).
 GCs were released much faster from SLNs compared 
to the cream ( fig. 1 ). Kinetic constants obtained from PC 
and BMV loaded to SLNs exceeded those following the 
respective cream more than 10-fold. PD release from 
SLNs was higher than from the cream, too, but less en-
hanced than PC and BMV release ( table  2 ). After 8 h, 
162.2  8 7.2   g of PD (i.e. about 30% of the total GC load-
ed), 54.6  8 5.3   g of PC (10.9%) and 23.5  8 5.0   g of 
BMV (4.7%) were released from the SLNs. Relative lag 
times corresponded to those for creams ranging from 0.2 
 8 0.1 h 0.5 (PD) to 1.0  8 0.1 h 0.5 (BMV). The higher ki-
netic constants for SLN dispersions can be attributed to 
the lower viscosity of the outer aqueous phase  [28] and to 
the increased thermodynamic activity of the GCs in the 
SLN dispersion due to the higher water content and there-
fore a decrease in the GC solubility in the formulation. 
Investigating volunteers Wirén et al.  [51] showed a higher 
activity of BMV (skin blanching) and benzyl nicotinate 













































 Fig. 1. Cumulative GC amounts released 
from cream ( a ) and SLNs ( b ); means  8 SD; 
 + = PD;  j = PC;  I = BMV; 500   g (284.1 
  g/cm 2 ) were applied to a polyamide 
membrane (Higuchi plot). 
Table 2. Results of the GC release studies
PD PC BMV
Cream
Flux, g/cm2/h0.5 9.9080.80 1.1680.14* 0.6580.07*
Relative lag time, h0.5 0.2180.03 0.7380.15* 1.2480.22*
R2 0.995 0.987 0.985
SLNs
Flux, g/cm2/h0.5 43.4487.42 14.6281.69* 7.3081.59*
Relative lag time, h0.5 0.1780.13 0.6880.10* 1.0380.11*
R2 0.982 0.994 0.986
5 00 g GC SLN dispersions or creams were applied for 8 h. 
Relative lag time and flux are given as mean values 8 SD (n = 9); 
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cal formulations which is attributed to a higher increase 
in drug concentration in the lower fat formulations with 
water evaporation when applied to the skin. A change of 
the thermodynamic activity caused by water evaporation 
during our experiments was, however, minimized, seal-
ing the donor compartment with Parafilm, and this can-
not explain the superiority of drug delivery by SLNs as 
compared to the cream.
 When testing GC-loaded SLNs, once more native PC 
(98.2  8 0.8% after 8 h) and PD (99.6  8 0.1%) were the 
main analytes detected in the receptor fluid, whereas BMV 
made up only 70.8  8 3.2% and the degradation products 
BM21V (26.8  8 2.7%) and BM (2.4  8 0.6%) were detect-
able in relevant amounts. Taken together, GC release from 
SLN is clearly superior to GC release from cream.
 Skin Uptake Studies: Cream 
 Drug release is of fundamental importance for topi-
cally applied formulations, yet the stratum corneum is 
the main barrier drugs have to overcome to penetrate into 
viable skin. Whereas release is normally controlled by 
diffusion processes in the formulation, skin uptake is ba-
sically influenced by the skin conditions – normal and 
diseased – and the physicochemical properties of the ac-
tive agent and the vehicle  [6, 52] and currently not to be 
predicted by computer-assisted models  [52] .  
 Uptake of the 3 steroids from the cream was studied 
in parallel using skin of 3 donors, and each cream was 
tested at least in triplicate on each skin. At the end of the 
exposure, the GCs were quantified in 100-  m horizon-
tal sections of the skin up to 400   m, and the total GC 
uptake is depicted in  figure 3 a. Regarding PC and BMV, 
varying amounts of metabolites were found in the skin. 
This can be a result of the esterase activity of the cryo-
conserved skin  [53] . These data are not shown because 
of the potential high interindividual variation in the es-
terase activity, yet PC and BMV penetration is reported 
as total drug which is the sum of native GC plus me-
tabolites. Applied for 6 h, 0.46   g PD had penetrated the 
skin, while with the others penetration was PC 0.16   g 
and BMV 0.12   g (median). In the first 100   m (main-
ly the epidermis), PD uptake from the cream exceeded 
PC and BMV uptake about 3-fold ( fig. 3 a; for mean up-
take 0–400   m, see  table 3 ), too. The difference between 
PC and BMV uptake is less obvious, but PC uptake was 
higher in each of the 3 donor skins. In deeper skin layers 
(200–400   m), the GC amounts were low for all of the 
3 steroids. Although the rank order of steroid penetra-
tion and release was identical, relating GC uptake and 
release (ratio,  table 3 ) shows BMV, the most lipophilic 
substance, to penetrate best, followed by PC. The clear-
ly lower skin uptake ratio despite an only minor differ-
ence in lipophilicity may be due to the slightly larger 
molecular volume of the PD diester (388.5 cm 3 /mol) and 
polar surface area (116.2 Å 2 ) as compared to the mono-
ester BMV (382.3 cm 3 /mol and 100.9 Å 2 ). In fact, the 
rank order of the ratios of GC skin uptake and release 
( table 3 ) is in accordance with the rank order of the per-
meability coefficients ( table 2 )  [39] .
 Skin Uptake Studies: SLN 
 To overcome the skin barrier, various colloidal drug 
carrier systems have been developed  [7, 12, 54–56] . SLNs 
have been studied intensively, yet the mechanism of en-
hancement is not clarified in full; lipid interactions of 
carrier and skin surface have been identified as a rele-
vant parameter  [12, 13] . Here, we studied the skin up-
take of GCs loaded to SLNs and applied for 6 h. As ob-
served before  [14, 15, 18] , SLNs enhanced drug penetra-
tion into the skin. Here, for the first time we compared 
the enhancement for a series of agents varying in lipo-
philicity, molecular volume and structure of the steroid 
moiety.
 Although the release of the steroids from cream and 
SLNs ranks in the same order, this does not hold true 


























 Fig. 2. Cumulative GC released from SLNs (means  8 SD);  + = 
PD 0.33–3 h, slope = 9.99   g/(cm 2 /h), R 2 = 0.983;  _ = PD 4–8 h, 
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 Fig. 3. Skin penetration of GCs added to 
base cream ( a ) and SLNs ( b ) after 6 h. Box 
plot with median, minimum, maximum 
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  g) penetration exceeds those of PD (1.72   g) and BMV 
(1.37   g; 0–400   m, mean value;  table 3 ). The overall 
1.5-fold difference with SLN dispersion is clearly less 
than the approximately 4-fold variation with GC creams. 
Thus, despite the importance of drug release, delivery 
by SLNs to the skin is strongly influenced by other prop-
erties, too. 
 The interaction of skin, vehicle and active ingredient 
controls the penetration of the active ingredient into the 
skin. The lipid content of a formulation can influence 
the thermodynamic activity of the active ingredient, re-
sulting in a modified penetration profile  [51] and pen-
etration enhancers like oleic acid and ethanol changing 
the ceramide organization within the skin, and can re-
versibly reduce the barrier function of the stratum cor-
neum  [57] . Changes of lipid structure by Poloxamer 
2.5% used for SLN stabilization have, however, been 
ruled out  [58] , and intact SLNs 175 nm in size should not 
penetrate the skin  [7] . In fact, no penetration was ob-
served with TiO 2 and ZnO particles less than 100 nm in 
size  [59, 60] either, as well as with Quantum dot nanopar-
ticles about 10 nm in size  [61] . Obviously the large sur-
face of the SLNs most efficiently interacting with skin 
surface lipids  [11–13] allows for a most efficient delivery 
to the skin surface rather independently of the lipophi-
licity of the agent and overruling the influences of mo-
lecular volume/molecular weight and the polar surface 
area of the GCs ( table 1 ). Once more, the permeability 
coefficient K p ( table  1 ) gains relevance as soon as the 
agent is released. It has to be kept in mind, however, that 
only 3 test agents of one substance class have been stud-
ied here. The lower penetration:release ratio when ap-
plying the SLN dispersions as with the cream indicates 
a saturation of the superficial skin layers due to the very 
efficient release from SLNs ( fig. 1 ).
 Epidermal Targeting 
 Differences in the cream and SLNs become even more 
obvious by drug distribution within the skin. Targeting 
to human epidermis was previously observed with the 
drug associated with the lipid particle surface  [15, 18, 19] . 
Incorporating the lipophilic dye Nile red into the matrix 
of the lipid nanoparticles showed no targeting effect us-
ing pig skin as test matrix  [12, 14] .
 Loading PD and PC to SLNs led to a clearly modified 
penetration profile compared to the cream ( fig. 3 b). This 
is seen with each donor skin (not shown). The epidermal 
enhancement given by the ratios between 0–100   m 
(containing the epidermis and upper parts of the der-
mis) and 100–200   m (dermis only) of the skin for PC 
and PD was clearly higher with SLNs as compared to the 
cream ( table 3 ). This does not hold true for BMV, the 
epidermal enhancement factors being 7.8 (cream) and 
7.9 (SLN), respectively, which is well in accordance with 
previous results  [19] . Although conclusions from these 
results ask for caution due to the high variation among 
the donors, epidermal targeting with PC and PD ap-
pears possible.
 Conclusion 
 Taken together, loading to SLNs increased GC release 
compared to base cream. Although for both formulations 
release followed the order PD  1 1 PC  1 BMV, only with 
the creams did penetration follow release. Yet, penetra-
Table 3. C omparison of the GC release and uptake by human skin after 6 h
Formulation Drug released 
after 6 h, g
Total skin uptake 
after 6 h, g





100 m:200 m 
(median)
SLN PD 151.9288.28 1.7280.54 1.13 17.3
SLN PC 45.0584.35 2.0680.70 4.57 10.8
SLN BMV 17.9584.11 1.3780.29 7.63 7.9
Cream PD 38.5383.32 0.6880.40 1.76 6.5
Cream PC 3.4880.12 0.2080.09 5.75 7.2
Cream BMV 1.3880.16 0.1680.11 11.59 7.8
Results are given as means 8 SD (n = 9 drug release and n = 3 skin uptake) and ratio of both in percent; the 
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